Tetsuji Shinohara Selected Research

HSP72 Heat-Shock Proteins

12/2011	Candesartan restored cardiac Hsp72 expression and tolerance against reperfusion injury in hereditary insulin-resistant rats.
11/2007	Hyperthermia treatment prevents angiotensin II-mediated atrial fibrosis and fibrillation via induction of heat-shock protein 72.
9/2007	Mitochondria are targets for geranylgeranylacetone-induced cardioprotection against ischemia-reperfusion in the rat heart.
8/2006	Pioglitazone but not glibenclamide improves cardiac expression of heat shock protein 72 and tolerance against ischemia/reperfusion injury in the heredity insulin-resistant rat.
7/2005	Effects of insulin resistance on geranylgeranylacetone-induced expression of heat shock protein 72 and cardioprotection in high-fat diet rats.
6/2005	Oral administration of geranylgeranylacetone blunts the endothelial dysfunction induced by ischemia and reperfusion in the rat heart.
11/2004	Estrogen inhibits hyperthermia-induced expression of heat-shock protein 72 and cardioprotection against ischemia/reperfusion injury in female rat heart.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tetsuji Shinohara Research Topics

Disease

12	Atrial Fibrillation 07/2022 - 11/2007
9	Heart Failure 02/2021 - 01/2011
9	Fibrosis (Cirrhosis) 01/2019 - 11/2007
7	Reperfusion Injury 12/2011 - 11/2003
6	Insulin Resistance 12/2011 - 07/2005
5	Brugada Syndrome 02/2021 - 08/2014
5	Ventricular Fibrillation 11/2020 - 02/2010
5	Heart Diseases (Heart Disease) 07/2020 - 09/2008
5	Inflammation (Inflammations) 01/2019 - 10/2011
5	Hyperthermia 12/2011 - 08/2006
4	Hemorrhage 06/2022 - 01/2020
4	Ischemia 09/2007 - 11/2003
3	Cardiac Sudden Death (Sudden Cardiac Arrest) 02/2021 - 08/2014
3	Hypoxia (Hypoxemia) 11/2018 - 05/2006
3	Obesity 01/2018 - 09/2008
3	Ventricular Tachycardia 02/2010 - 11/2003
2	Shock 02/2021 - 08/2014
2	Spasm (Spasms) 12/2020 - 01/2018
2	Hyperglycemia 07/2020 - 01/2016
2	Sick Sinus Syndrome 01/2019 - 04/2012
2	Atrial Remodeling 01/2018 - 01/2016
2	Sarcoidosis (Schaumann Disease) 01/2017 - 04/2012
2	Stroke (Strokes) 01/2011 - 07/2010
2	Myocardial Infarction 01/2011 - 07/2010
1	Cardiac Arrhythmias (Arrythmia) 10/2022
1	Hematoma 06/2022
1	Peripheral Nervous System Diseases (PNS Diseases) 06/2022
1	False Aneurysm (Pseudoaneurysm) 06/2022
1	Thromboembolism 02/2021
1	Fever (Fevers) 01/2021
1	Syncope (Fainting) 11/2020
1	Hypoglycemia (Reactive Hypoglycemia) 07/2020
1	Lipidoses 01/2018
1	Thrombosis (Thrombus) 01/2018
1	Body Weight (Weight, Body) 06/2017
1	Dilated Cardiomyopathy (Cardiomyopathy, Congestive) 01/2017
1	Wolff-Parkinson-White Syndrome (Wolf-Parkinson-White Syndrome) 01/2017
1	Left Ventricular Dysfunction 01/2017
1	Paroxysmal ventricular fibrillation 08/2014
1	Sinus Tachycardia 08/2014
1	Tachycardia (Tachyarrhythmias) 05/2011

Drug/Important Bio-Agent (IBA)

7	HSP72 Heat-Shock ProteinsIBA 12/2011 - 11/2004
6	Insulin (Novolin)FDA Link 12/2011 - 07/2005
3	Glucose (Dextrose)FDA LinkGeneric 07/2020 - 07/2005
3	Interleukin-10 (Interleukin 10)IBA 01/2019 - 01/2016
3	Angiotensin IIIBA 04/2013 - 11/2007
3	Creatine Kinase (Creatine Phosphokinase)IBA 05/2009 - 11/2003
3	geranylgeranylacetone (teprenone)IBA 09/2007 - 06/2005
2	Biomarkers (Surrogate Marker)IBA 01/2022 - 02/2021
2	edoxabanIBA 01/2022 - 02/2021
2	Pharmaceutical PreparationsIBA 01/2021 - 09/2007
2	C-Reactive ProteinIBA 01/2020 - 10/2011
2	AnticoagulantsIBA 01/2020 - 01/2018
2	Streptozocin (Streptozotocin)FDA Link 01/2019 - 11/2003
2	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2019 - 01/2016
2	CytokinesIBA 11/2018 - 01/2018
2	LeptinIBA 06/2017 - 04/2013
2	salicylhydroxamic acid (SHAM)IBA 01/2016 - 05/2011
2	Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA 12/2011 - 08/2006
2	Phosphatidylinositols (Phosphatidylinositol)IBA 12/2011 - 08/2006
2	AdiponectinIBA 10/2011 - 07/2007
2	Isoproterenol (Isoprenaline)FDA LinkGeneric 09/2010 - 02/2010
2	mitochondrial K(ATP) channelIBA 05/2009 - 09/2007
1	Vasodilator Agents (Vasodilators)IBA 12/2020
1	Hypoglycemic Agents (Hypoglycemics)IBA 07/2020
1	Cyclic NucleotidesIBA 01/2019
1	Potassium Channels (Potassium Channel)IBA 01/2019
1	Matrix Metalloproteinase 2 (Gelatinase A)IBA 11/2018
1	ChemokinesIBA 11/2018
1	Factor Xa (Coagulation Factor Xa)IBA 01/2018
1	Proteinase-Activated ReceptorsIBA 01/2018
1	RivaroxabanIBA 01/2018
1	Hydroxyproline (4 Hydroxyproline)IBA 06/2017
1	N-formyl-13-dihydrocarminomycin (NFD)IBA 06/2017
1	Messenger RNA (mRNA)IBA 01/2016
1	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 01/2016
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2016
1	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2016
1	Norepinephrine (Noradrenaline)FDA LinkGeneric 09/2014
1	Bepridil (Vascor)FDA Link 08/2014
1	Cilostazol (Pletal)FDA LinkGeneric 08/2014
1	AntioxidantsIBA 12/2012
1	NADPH Oxidases (NAD(P)H oxidase)IBA 12/2012
1	Adrenal Cortex Hormones (Corticosteroids)IBA 04/2012
1	Iodine-123IBA 01/2012
1	candesartanIBA 12/2011
1	Telmisartan (Micardis)FDA Link 10/2011

Therapy/Procedure

7	Implantable Defibrillators (Implantable Cardioverter-Defibrillator) 07/2022 - 08/2014
6	Catheter Ablation 01/2022 - 02/2009
6	Therapeutics 02/2021 - 06/2008
5	Cardiac Resynchronization Therapy 02/2021 - 10/2011
2	Percutaneous Coronary Intervention 06/2022 - 01/2011
2	Induced Hyperthermia (Thermotherapy) 05/2006 - 11/2004
1	Drug Therapy (Chemotherapy) 10/2022
1	Punctures 06/2022
1	Catheters 06/2022
1	Patient Readmission 01/2020
1	Splenectomy 01/2016
1	Defibrillators (Defibrillator) 02/2015
1	Denervation 04/2012